RxDoctor Payments Data

Timothy Short, NP

Family · Adrian, MINPI 1114696069

Payments from drug & device makers

$1,708in general payments, 2019–2025

Across 101 payments — averaging $16.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$268
  • AstraZeneca$262
  • Pfizer$232
  • Lilly USA, LLC$209
  • Novo Nordisk$166
  • GSK$165
  • plus $406 from 8 others

What the payments were for

  • Food & beverage$1,708100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,708 in reported general payments places this provider in the 80th percentile of 3,657 family providers in Michigan.

See all family providers in Michigan

Medicare billing

Part B allowed, 2024
$17,701
Medicare patients
57
Services billed
238

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PamelorNortriptyline Hcl17$98,294
OzempicSemaglutide28$50,180
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,542
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,909
Acyclovir12$3,243
Albuterol Sulfate HfaAlbuterol Sulfate72$2,553
Desvenlafaxine Succinate ErDesvenlafaxine Succinate31$1,330
Atorvastatin Calcium118$1,137
Pantoprazole Sodium50$1,063
Montelukast Sodium82$1,043
Pregabalin16$1,017
Gabapentin59$946
Celecoxib23$929
Potassium Chloride30$874
Levothyroxine Sodium63$681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$166$50,18028 claims
GSKTrelegy Ellipta$165$14,54219 claims
Lilly USA, LLCOlanzapine$209$26724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,657 family providers in Michigan.

Other family in Adrian

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →